ϩ (KATP) channels by an increase in the ATP/ADP ratio and the resultant membrane depolarization are considered essential in the process leading to insulin release (IR) from pancreatic ␤-cells stimulated by glucose. It is therefore surprising that mice lacking the sulfonylurea type 1 receptor (SUR1 Ϫ/Ϫ ) in ␤-cells remain euglycemic even though the knockout is expected to cause hypoglycemia. To complicate matters, isolated islets of SUR1 Ϫ/Ϫ mice secrete little insulin in response to high glucose, which extrapolates to hyperglycemia in the intact animal. It remains thus unexplained how euglycemia is maintained. In recognition of the essential role of neural and endocrine regulation of IR, we evaluated the effects of acetylcholine (ACh) and glucagon-like peptide-1 (GLP-1) on IR and free intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) of freshly isolated or cultured islets of SUR1 Ϫ/Ϫ mice and B6D2F1 controls (SUR1 ϩ/ϩ ). IBMX, a phosphodiesterase inhibitor, was also used to explore cAMP-dependent signaling in IR. Most striking, and in contrast to controls, SUR1 Ϫ/Ϫ islets are hypersensitive to ACh and IBMX, as demonstrated by a marked increase of IR even in the absence of glucose. The hypersensitivity to ACh was reproduced in control islets by depolarization with the SUR1 inhibitor glyburide. Pretreatment of perifused SUR1 Ϫ/Ϫ islets with ACh or IBMX restored glucose stimulation of IR, an effect expectedly insensitive to diazoxide. The calcium channel blocker verapamil reduced but did not abolish ACh-stimulated IR, supporting a role for intracellular Ca 2ϩ stores in stimulussecretion coupling. The effect of ACh on IR was greatly potentiated by GLP-1 (10 nM). ACh caused a dose-dependent increase in [Ca 2ϩ ]i at 0.1-1 M or biphasic changes (an initial sharp increase in [Ca 2ϩ ]i followed by a sustained phase of low [Ca 2ϩ ]i) at 1-100 M. The latter effects were observed in substratefree medium or in the presence of 16.7 mM glucose. We conclude that SUR1 deletion depolarizes the ␤-cells and markedly elevates basal [Ca 2ϩ ]i. Elevated [Ca 2ϩ ]i in turn sensitizes the ␤-cells to the secretory effects of ACh and IBMX. Priming by the combination of high [Ca 2ϩ ]i, ACh, and GLP-1 restores the defective glucose responsiveness, precluding the development of diabetes but not effectively enough to cause hyperinsulinemic hypoglycemia. calcium INHIBITION of ATP-sensitive K ϩ (K ATP ) channels by an increase in the ATP/ADP ratio and the resultant depolarization are considered essential for the physiological mechanisms that lead to insulin secretion from pancreatic ␤-cells stimulated by high glucose (3, 8, 39) . Functional K ATP channels of the pancreatic ␤-cell are a heterooctameric combination of K ϩ inward rectifiers (K IR 6.2) and sulfonylurea receptors (SUR1) (1). These channels couple fuel metabolism to membrane electrical activity, which results in the [Ca 2ϩ ] i accumulation necessary to promote exocytosis (1).
INHIBITION of ATP-sensitive K
ϩ (K ATP ) channels by an increase in the ATP/ADP ratio and the resultant depolarization are considered essential for the physiological mechanisms that lead to insulin secretion from pancreatic ␤-cells stimulated by high glucose (3, 8, 39) . Functional K ATP channels of the pancreatic ␤-cell are a heterooctameric combination of K ϩ inward rectifiers (K IR 6.2) and sulfonylurea receptors (SUR1) (1) . These channels couple fuel metabolism to membrane electrical activity, which results in the [Ca 2ϩ ] i accumulation necessary to promote exocytosis (1) .
Mutations in human SUR1 or K IR 6.2 cause a recessive form of persistent hyperinsulinemic hypoglycemia of infancy characterized by oversecretion of insulin despite severe hypoglycemia (10, 36) . To understand the metabolic basis of this disorder and the role of K ATP channels in glucose homeostasis, three mouse models were developed that involve the disruption of K ATP channels: 1) expression of a dominant negative mutant K IR 6.2 subunit that reduces or eliminates K ATP channel activity (28) ; 2) K IR 6.2 knockout (27) ; and 3) SUR1 (33, 35) knockout. It is noteworthy that transgenic mice with mutated K IR 6.2 G132S are only mildly hypoglycemic at birth but become hyperglycemic within 4 wk as a result of ␤-cell destruction (28) . The deletion of SUR1 (33, 35) or Kir 6.2 (27) from mouse pancreatic ␤-cells has unexpectedly little or no effect on glucose homeostasis in contrast to the predicted hypoglycemic phenotype. SUR1 knockout mice exhibit normal insulin release in response to feeding but do not secrete insulin in response to parenteral glucose (35) . Furthermore, ␤-cells are unable to increase insulin release when stimulated with high glucose in a variety of extracorporeal test systems (33, 35) . The lack of a glucose response should have caused hyperglycemia in the intact animal. The nature of the adaptations required to maintain euglycemia remains unexplained.
In normal animals, feeding elicits acetylcholine (ACh) release by intrapancreatic nerve endings (13) and glucagon-like peptide-1 (GLP-1) release from the intestine (16) . On the basis of this basic physiology and in light of the ability of the islet to respond to feeding, we have evaluated the effect of ACh, GLP-1, and IBMX on insulin release and free intracellular Ca 2ϩ of freshly isolated or cultured islets of SUR1 Ϫ/Ϫ knockout mice and B6D2F1 controls (SUR1 ϩ/ϩ ). We found that pancreatic islets from SUR1 knockout mice are hypersensitive to ACh, as demonstrated by a marked increase of insulin release even in the absence of glucose. ACh also restitutes glucose-induced insulin secretion, and its effect is potentiated by GLP-1. The ability of SUR1 knockout mice to maintain normoglycemia may be explained by neuroendocrine modification of ␤-cell function.
RESEARCH DESIGN AND METHODS
Animal. SUR1 knockout mice were generated as described (35) . The SUR1 Ϫ/Ϫ mice contained a mutation that was made in RW4 ES cells (129/SvJ origin). They had been backcrossed three times into C57Bl/6. The mice were maintained on a 12:12-h light-dark cycle and were fed a standard rodent chow diet. B6D2F1 mice (SUR ϩ/ϩ ; Jackson Labs) were used as controls.
Islet isolation. Mouse islets were isolated using collagenase (EC 3.4.24.3; Serva, 17449) digestion in Hanks' buffer followed by separation of islets from exocrine tissue in a Ficoll (Sigma, F-9378) gradient. Isolated islets were used fresh or cultured for 4 days in RPMI 1640 medium (GIBCO BRL, Grand Island, NY) containing 10% fetal bovine serum, 10 ml/l penicillin-streptomycin-amphotericin B solution (GIBCO BRL), and 10 mM glucose (34) .
Perifusion of islets and insulin release experiments. Freshly isolated islets were placed on a nylon filter in a plastic perifusion chamber (Millipore, Bedford, MA). The perifusion apparatus consisted of a computer-controlled fast-performance HPLC system (Waters 625 LC System) that allowed programmable rates of flow and glucose concentration in the perfusate, a water bath (37°C), and fraction collector (Waters Division of Millipore). The perifusate was a Krebs buffer (pH 7.4) containing 2.2 mM Ca 2ϩ and 0.25% of bovine serum albumin equilibrated with 95% O2-5% CO2. In some studies, islets were preperifused with no substrate for 30 min followed by a glucose ramp with a slope of 0.8 mM glucose/min. The maximal islet response was tested at the end of experiment with 30 mM KCl after washout of glucose.
Glucokinase assay. The enzyme was measured using a spectrometric plate reader and was based on a coupled NAD ϩ -dependent assay (38) . Islets were homogenized in a buffer with 150 mM KCl, 2 mM dithiothreitol, and proteinase inhibitors and briefly spun at 1,000 g. With use of aliquots of the homogenate equivalent to ϳ20 islets per well, the V max, the glucose level at half-maximal activity of glucokinase, the ATP Km, and the Hill number indicating cooperativity with the substrate glucose were determined at 37°C with reaction progress curves extending to 90 min. Other hexokinases (primarily subtype I) were blocked by 40 M 5-desoxy-5-fluoro-G-6-P. Ca 2ϩ measurement. Mouse islets, cultured for 4 days in 10 mM glucose, were loaded with fura-2 AM (Molecular Probes, Eugene, OR) during a 40-min pretreatment at 37°C in 2 ml of Krebs Ringer bicarbonate buffer (KRBB) supplemented with 1 mmol/l fura-2 AM. The loaded islets were transferred to the perifusion chamber and placed on the homeothermic platform of an inverted Zeiss microscope (12) . Islets were perfused with KRBB at 37°C at a flow rate of 2 ml/min, while various treatments were applied to the islets. The microscope was used with a 40ϫ oil immersion objective. The intracellular Ca 2ϩ was determined by the ratio of the excitation of fura at 334 and 380 nm. Emission was measured at 520 nm by a Attofluor charge-coupled device camera and calibrated using the Attofluor Ratio Vision Software.
Insulin measurements. Insulin in the effluent was measured by radioimmunoassay with charcoal separation (17) . Rat insulin from Linco Research served as standard, and Miles anti-insulin antibody from ICN was the primary antibody.
Statistical analysis. Data are presented as the means Ϯ SE of 4 -7 experiments. In appropriate cases, significant differences between groups were determined by one-way analysis of variance (ANOVA) with post hoc analysis using Dunnett's multiple-comparison test. Values of P Յ 0.05 were accepted as significant.
RESULTS

Hypersensitivity of SUR1
Ϫ/Ϫ islets to ACh. Figure 1A shows insulin secretion of control and SUR1 Ϫ/Ϫ islets during stimulation with glucose. In these experiments, the glucose concentration was increased progressively from 0 to 30 mM by 0.8 mM increment/min. Insulin release was not affected by glucose in SUR1
Ϫ/Ϫ islets, in contrast to a significant increase in hormone secretion in pancreatic islets from control mice. To test whether this effect was caused by a change in glucose metabolism, we measured glucokinase activity as one of the most critical parameters in freshly isolated and cultured islets from both sets of mice. We found glucokinase activity and kinetics of freshly isolated islets and of islets cultured for 4 days at 10 mM glucose to be normal ( Table 1 ). The data suggest that, with the assumption of normal oxidation, the lack of glucose responsiveness is not caused by reduced glucose metabolism. We found that glucose responsiveness may be regained when islets are pretreated with ACh, GLP-1, or IBMX, as exemplified in the following experiments. A gradual increase in the concentration of ACh from 0 to 500 M in the presence of 16.7 mM glucose and 10 M of the cholinesterase inhibitor neostigmine caused a burst of insulin secretion in SUR1 Ϫ/Ϫ islets (Fig. 1B) . Removal of ACh from the perifusate decreased the hormone release. In the next sets of experiments, 100 M or 0.3 M ACh was added to control and SUR1 Ϫ/Ϫ islets during perifusion with substrate-free media (Fig. 1, C and  D) . In contrast to controls, SUR1 Ϫ/Ϫ islets responded to high and low concentrations of ACh by a significant increase in insulin release, even in the absence of glucose, indicating hypersensitivity of SUR1 Ϫ/Ϫ islets to the cholinergic agonist. After 30 min of preperfusion with ACh, a glucose ramp (from 0 to 30 mM with an 0.8-mM increment/min) was applied to control and SUR1 Ϫ/Ϫ islets. The graded rise of glucose in the perifusate led to graded increase in hormone secretion in SUR1 Ϫ/Ϫ islets as well as in the control islets. However, the kinetics of the hormone release were different in the two groups of islets, an initial burst of insulin release in the controls as glucose rose from 0 to 10 mM contrasting with a gradual increase of insulin release in SUR1 Ϫ/Ϫ islets as the glucose increased from 0 to 30 mM. High concentrations of ACh significantly lowered the threshold for glucose-stimulated insulin release in control islets, whereas at low concentrations of ACh, islets exhibited a normal threshold for insulin release at 5-6 mM glucose. Diazoxide, a K ATP channel activator, reduced insulin release back to baseline in control islets in contrast to sustained hormone release in SUR1 Ϫ/Ϫ islets. Detailed studies with 10 and 1 M ACh demonstrated a clear dose dependency of action (data are not shown).
Effect of verapamil on ACh-stimulated insulin release. To evaluate the role of extracellular Ca 2ϩ in ACh-mediated insulin release, the Ca 2ϩ channel blocker verapamil was added to perifusate containing 16.7 mM glucose. Fifteen minutes later the acetylcholine ramp was applied. Verapamil decreased but did not abolish ACh-stimulated insulin release (compare Fig.  1B and Fig. 2 ), indicating partial dependence on Ca 2ϩ influx E835 and a prominent role of intracellular Ca 2ϩ in stimulus-secretion coupling.
GLP-1 potentiates the ACh effect on insulin release. In view of the supposition that pancreatic islets in vivo could be simultaneously stimulated by glucose and neuroendocrine factors, we tested the effect of GLP-1 on insulin release in SUR1 Ϫ/Ϫ (Fig. 3A) and control ( Fig. 3B ) islets. The effect of GLP-1 was significantly smaller in SUR1 Ϫ/Ϫ islets compared with control. Most striking is the finding that, in all experiments, GLP-1 potentiated the effect of ACh on insulin release two-to threefold (Fig. 3A) to a level that is comparable to that of normal islets perfused with high glucose, GLP-1, and ACh.
Changes ] i (Fig. 4B) . ACh in the presence of 16.7 mM glucose caused a dose-dependent Ϫ/Ϫ islets in the absence of glucose, suggesting marked hypersensitivity to the transmitter. After 30 min of preperfusion with ACh, a glucose ramp (from 0 to 30 mM with an 0.8 mM increment/min rate) was applied to control and SUR1 Ϫ/Ϫ islets. Increase in the glucose concentration in the perfusate led to an increase in hormone secretion in SUR1 Ϫ/Ϫ islets as well as in controls. Diazoxide, an ATP-sensitive K ϩ (KATP) channel activator, immediately decreased insulin release to baseline in control but was unable to block hormone release in SUR1 Ϫ/Ϫ islets. Each curve in A and B represents the mean Ϯ SE of 5-7 perifusions. Data in C and D are means of 4 -6 perfusions without SE. increase in [Ca 2ϩ ] i (at 0.1-1 M ACh; Fig. 5, A-C ] i levels to slightly higher than baseline.
Effect of IBMX on insulin release in SUR1 Ϫ/Ϫ islets. It has been shown recently that carbamylcholine evokes a concentration-dependent increase in cAMP generation in normal rat ␤-cells with a maximum increase Ն4.5-fold above control (37) . GLP-1 also increased cAMP level in pancreatic ␤-cells (13) . On the basis of these data, we hypothesized that an increase in cAMP might mimic the effect of ACh (or ACh plus GLP-1) on insulin release in SUR1 Ϫ/Ϫ islets. Figure 6A shows that the phosphodiesterase inhibitor IBMX causes a dosedependent increase in insulin release in the presence of 16.7 mM glucose in control and SUR1 Ϫ/Ϫ islets, with a much higher increase seen in the control islets. In contrast to control islets, IBMX was able to increase insulin release in SUR1 Ϫ/Ϫ islets in the absence of glucose (Fig. 6B) . Increasing the glucose concentration from 0 to 30 mM in the presence of IBMX led to biphasic changes in insulin release in SUR1 Ϫ/Ϫ islets. Initially, insulin secretion decreased, was then followed by a rapid increase at 5-6 mM glucose, and was maximal at ϳ10 mM glucose. Control islets exhibited a graded increase in insulin secretion after the glucose concentration reached the threshold of 5-6 mM. This glucose effect was insensitive to diazoxide in SUR1 Ϫ/Ϫ islets, whereas control islets responded by a return of insulin release to baseline (Fig. 6B) (Fig. 6C) .
Cell depolarization by glyburide increases sensitivity of islets to ACh. Because SUR1
Ϫ/Ϫ islets are permanently depolarized, it is reasonable to speculate that this primary abnormality sensitized ␤-cells to ACh. To test this hypothesis, an ACh ramp (from 0 to 100 M) was applied to control islets, which were depolarized by the SUR1 inhibitor glyburide. Glyburide slightly increased insulin release, tripled cytosolic Ca 2ϩ in glucose-free medium, and markedly sensitized islets to ACh (Fig. 7) . The ACh response was biphasic: a sharp increase as ACh increased from 0 to 30 M, followed by inhibition as the transmitter dose was raised further to 100 M (Fig. 7A) . ␤-Cell depolarization by glyburide led to increased [Ca 2ϩ ] i in glucose-free medium (Fig. 7B) . Under these conditions, ACh induced a further increase in [Ca 2ϩ ] i followed by a sustained phase of relatively low [Ca 2ϩ ] i (Fig. 7B) , supporting the hypothesis that cell depolarization may increase the sensitivity to ACh in normal islets.
DISCUSSION
The results of the present study indicate that glucose is able to stimulate insulin release from pancreatic islets of SUR1 knockout mice provided that a combination of the following conditions is met (Fig. 8) : an increased phosphorylation potential, which requires that glucokinase activity be normal (pathway 1); elevated basal cytosolic Ca 2ϩ (pathways 2 and 4); activation of protein kinase C (pathway 3); elevated cAMP levels and activation of the cAMP-guanidine nucleotide exchange factor II (GEFII) pathway (pathway 5); and activation of protein kinase A (pathway 6). We discuss these signaling pathways in the following paragraphs on the basis of present results and data in the literature.
SUR1 deletion depolarizes the ␤-cells because functional K ATP channels are absent. Voltage-dependent Ca 2ϩ channels Values are means Ϯ SE. Islets were frozen immediately after isolation or after culturing for 4 days in RPMI at 10 mM glucose. Glucokinase was then measured spectrophotometrically in a tissue homogenate cleared of heavy particles by brief low-speed centrifugation. Insulin refers to the cumulative 48-h level in culture media during the 2nd half of the 4-day incubation. The wide range of levels is explained by the significant variation in islet number among experiments. SUR1 Ϫ/Ϫ , sulfonylurea type 1 receptor; S0.5, glucose level at half-maximal activity of glucokinase; nH, Hill number indicating cooperativity with the substrate glucose.
are opened, and basal intracellular Ca 2ϩ is markedly elevated. We show here that basal intracellular Ca 2ϩ concentrations are significantly higher in SUR1 Ϫ/Ϫ islets compared with controls, in agreement with previous studies (35) . Yet these islets do not secrete insulin under these conditions. Eliasson et al. (11) conclude that the lack of the secretory responses in SUR1 Ϫ/Ϫ ␤-cells is not attributable to decreased insulin content, which averaged 280 Ϯ 19 ng insulin/islet and 253 Ϯ 10 ng/islet in wild-type and SUR1 Ϫ/Ϫ mice, respectively (11). However, Shiota et al. (35) and Nakazaki et al. (30) reported reduction in actual insulin content in the SUR1 Ϫ/Ϫ pancreas by ϳ60 and 43-55%, respectively, compared with the wild-type pancreas. The difference in results is not explained.
Depolarization elevates Ca
2ϩ and may in turn sensitize the ␤-cells to the action of ACh. It was indeed observed that SUR1 knockout islets are hypersensitive to the cholinergic agonist and that ACh stimulates insulin release even in the absence of glucose. This is in contrast with normal islets: here ACh does not augment insulin secretion, nor does it change intracellular Ca 2ϩ concentrations in the absence of glucose (26) . These data complement the results of Shiota et al. (35) obtained with perfused pancreata by use of carbachol and of Nakazaki et al. (30) with perifused islets by use of the protein kinase C activator 12-O-tetradecanoylphorbol 13-acetate (TPA) or carbamylcholine. In both of these studies, cholinergic agonists or TPA stimulated insulin release at low (2.8 -3 mM) 
A: SUR1
Ϫ/Ϫ islets were pretreated with 16.7 mM glucose. At 30 min, GLP-1 was added to one set of islets while the second set of islets continued to be perfused with 16.7 mM glucose alone. Ten minutes later, ACh was added to both perifusions. B: experiments with control islets were done in the same order as in A with GLP-1. Each curve is the mean Ϯ SE of 6 -7 perifusions. glucose in wild-type and in SUR1 Ϫ/Ϫ islets, with greater amplitude in SUR1 Ϫ/Ϫ islets. The authors concluded that SUR1 Ϫ/Ϫ mice remain responsive to cholinergic agonists; however, they did not stress the fact that the mice are hypersensitive to ACh.
The hypersensitivity to ACh can be reproduced in control islets by treatment with the SUR1 inhibitor glyburide as one might predict. These new observations expand and clarify previous studies with ACh in the SUR1 knockout mouse (30, 35) .
Pretreatment with ACh leads to restitution of glucose-induced insulin secretion in perifused islets of SUR1 knockout mice. However, the insulin secretion dynamics are different from those of normal islets, indicating that the network of signaling pathways has been altered. Normal islets exhibit a threshold for insulin release at 5-6 mM glucose (both in the absence and the presence of 0.3 M ACh); pretreated SUR1 Ϫ/Ϫ islets have, however, a much lower glucose threshold and begin to respond to glucose at 1 mM or even less. Furthermore, insulin release in SUR1 Ϫ/Ϫ islets does not rise as rapidly as in controls during the glucose ramp and is not sensitive to diazoxide, consistent with a situation in which the K ATP channel has been eliminated. Figure 8 (pathway 3) presents the mechanisms by which ACh may affect ␤-cells. When ACh binds to M 3 receptors, it activates several transduction pathways; one is phospholipase C, which generates inositol 1,4,5-trisphosphate and diacylglycerol, a potent protein kinase C activator (13, 37) . ACh could also depolarize the plasma membrane of ␤-cells by a Na ϩ -or nonspecific cationdependent mechanism, and possibly by a mechanism involving store-operated channels activated by intracellular Ca 2ϩ pool emptying. This additional depolarization may increase the probability of the open state of voltage-dependent Ca 2ϩ channels in the plasma membrane already depolarized by the SUR1 knockout. Verapamil, a calcium channel blocker, reduces ACh-stimulated insulin release in SUR1 knockout mice, suggesting partial dependence on Ca 2ϩ influx in a situation in which a prominent role of intracellular Ca 2ϩ stores in stimulus-secretion coupling has been clearly demonstrated.
GLP-1 alone has a small effect, but it significantly potentiates ACh-stimulated insulin release in the presence of high glucose (Fig. 3) . Previously published data (30, 35) showed that GLP-1 stimulates insulin secretion from wild-type but not from SUR1
Ϫ/Ϫ islets. The apparent lack of response of SUR1 Ϫ/Ϫ islets to GLP-1 was not due to altered coupling of GLP-1 receptors with adenylyl cyclase, because GLP-1 increased the islet cAMP content in wild-type and SUR1 Ϫ/Ϫ islets to a comparable degree (30) . In addition, the impaired response to GLP-1 did not appear to result from a defect in exocytosis or altered protein kinase A (30) . It was suggested that a defect might exist in the PKA-independent potentiation of insulin release by cAMP (30) . The phosphodiesterase inhibitor IBMX and activator of adenylyl cyclase forskolin were also employed to manipulate the cAMP content in islets (30) . It was found that the secretory response of SUR1 Ϫ/Ϫ islets was impaired compared with wild-type islets, whereas the intracel- E839 lular cAMP content was elevated similarly in both wild-type and SUR1
Ϫ/Ϫ islets treated with forskolin and IBMX, alone or in combination. On the basis of these data, it was speculated that a reduced islet response to GLP-1 and impaired PKAindependent potentiation of insulin release by cAMP may prevent the hypoglycemia expected to occur in these knockout animals. However, Eliasson et al. (11) showed recently that GLP-1 and forskolin potentiate glucose-induced secretion from SUR1 Ϫ/Ϫ islets 2.2-to 2.8-fold, which is only slightly less than the amount seen in normal animals. These data contrast with in vivo experiments on the same SUR1 Ϫ/Ϫ mouse strain that suggest the complete loss of GLP-stimulated secretion (35) . The authors (11) suggest that the PKA-independent action of cAMP on exocytosis plays an important role in incretinstimulated insulin secretion in vivo.
Our data show that isolated SUR1 Ϫ/Ϫ islets respond to IBMX by increasing insulin release in a dose-dependent manner but at a lower magnitude than normal islets. The threshold for IBMX-stimulated insulin release is 150 M. However, the more striking finding is that SUR1 Ϫ/Ϫ islets respond to IBMX in the absence of glucose, an effect not seen in normal islets. Pretreatment with IBMX restored glucose-stimulated insulin release in SUR1 Ϫ/Ϫ islets with a threshold of ϳ5-6 mM. It is remarkable that low glucose decreased insulin release in the presence of IBMX. This effect, also seen in the Ca 2ϩ fluorescence tracings, could have several explanations, which were not further explored. Nakazaki et al. (30) showed that forskolin, added together with a high concentration of IBMX, stimulates insulin release in SUR1 Ϫ/Ϫ islets even at low (2.8 mM) glucose. However, IBMX (500 M) or forskolin alone did not stimulate insulin release in SUR1 Ϫ/Ϫ islets at high (16.7 mM) glucose. These data are different from ours, which show that a lower concentration of IBMX and high glucose had significant effects on insulin release in SUR1 Ϫ/Ϫ islets. In support of our data, Eliasson et al. (11) reported recently that islets from SUR1 Ϫ/Ϫ mice responded well to forskolin and GLP-1, although the magnitude of the responses was only 50% of that seen in wild-type islets. The synergy of GLP-1 and ACh in insulin secretion may be due to simultaneous activation of PKA by GLP-1 (16) and of PKC by ACh (37) (Fig. 8, pathways 3 and 6) . It has been shown before that glucose augments insulin release markedly, even in the absence of extracellular Ca 2ϩ , when PKA and PKC are activated simultaneously (23) . Komatsu et al. (24) demonstrated that the combination of the pituitary adenylate cyclase activation peptide (PACAP), carbachol, and glucose stimulated insulin release in the absence of the elevation of [Ca 2ϩ ] i . It should be remembered in this context that ACh sensitizes the secretory machinery to Ca 2ϩ (14, 25) . cAMP promotes exocytosis in the pancreatic ␤-cells by a PKA-independent mechanism (Fig. 8, pathway 5) as well as by a PKA-dependent mechanism (pathway 6) (21, 32). Kawasaki et al. (22) reported that the cAMP-binding protein cAMP-GEFII, also referred to as Epac2 (6, 9) , is a direct target of cAMP, thus regulating exocytosis, and that cAMP-GEFII, interacting with Rim2 (a target of the small G protein Rab3), mediates cAMP-dependent, PKA-independent exocytosis in a reconstituted system (31) . It seems that cAMP-GEFII mediates cAMP-dependent PKA-independent mobilization of Ca 2ϩ from the endoplasmic reticulum Ca 2ϩ stores through ryanodine receptor-regulated Ca 2ϩ channels (19 Ϫ/Ϫ islets probably due to PLC-catalyzed production of IP 3 and stimulation of specific IP 3 receptors of intracellular Ca 2ϩ stores (see pathway 3 in Fig. 8 ). It is noteworthy that at concentrations higher than 1 M, ACh did actually lower [Ca 2ϩ ] i during the sustained second phase and that this effect was associated with stimulation of insulin release. Such an effect of ACh was observed in control islets by others (13) and is related to an increased efficacy of Ca 2ϩ on exocytosis due to simultaneous activation of pathways 3 and 6, as presented in Fig. 8 .
The present investigation underscores some of the shortcomings of widely held concepts and terminologies regarding stimulus-secretion coupling in pancreatic ␤-cells. The terms "K ATP channel-dependent" and "K ATP channel-independent" pathways are used to characterize distinct dual glucose actions leading to insulin release. The first action depolarizes the cell, which results in the activation of the voltage-dependent Ca 2ϩ channels, elevated Ca 2ϩ , and triggering of insulin release. The second augments the efficacy of the first by metabolic coupling factors of still unspecified chemical nature and mode of action. The intensive studies with the SUR1 knockout mouse (11, 30, 35) , including the present results, demonstrate that this conceptual framework has limited explanatory power and needs modification.
The K ATP channel-dependent or triggering pathway is constitutively activated by the SUR1 knockout, which is equivalent to channel inhibition and membrane depolarization and is manifested by high Ca 2ϩ . The K ATP channel-independent or augmentation pathway is operative as indicated by normal glucokinase levels, suggesting normal glucose metabolism and ATP production. Glucose is, however, ineffective in SUR1 knockout islets, even though the critical conditions of high Ca 2ϩ and normal sensing by glucokinase are both met. We speculate that signaling pathways 3, 5, and 6 (see Fig. 8 ), which are normally activated by high glucose via Ca 2ϩ , are not operative in SUR1 knockout islets, possibly due to persistently high Ca 2ϩ , but that ACh and/or GLP-1 is capable of bypassing such a block and of restituting these essential requirements for glucose-stimulated insulin release. Much work is required to test this hypothesis.
It seems then reasonable to conclude that neural and endocrine regulation, in particular by ACh and GLP-1, could determine insulin secretion in mice lacking SUR1. Priming by the combination of high Ca 2ϩ , ACh, and GLP-1 restores a defective glucose responsiveness. The restitution of glucosestimulated insulin release precludes the development of diabetes, but it is probable that it is not effective enough to cause the hyperinsulinemic hypoglycemia that was expected to develop as a result of the SUR1 knockout.
The present observations and considerations have practical implications for the widely used treatment of type 2 diabetes with SUR1 inhibitors. As shown here (i.e., Fig. 7 and by inference Figs. 3 and 6 ), SUR1 inhibitors sensitize the ␤-cells to incretins and ACh, which play an important role in maintaining glucose homeostasis. This sensitizing effect could be very pronounced, as demonstrated here, and could contribute in a critical manner to the efficacy and long-term benefit of diabetes therapy with SUR1 inhibitors. Such aspects of SUR1 inhibitor pharmacology deserve increased attention.
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